You are right. I expected to see that they had 10-15 million cash in hand but they have less than 1 million, will need to dilute to raise money. Stay away from here. Thought they would have learned by now. Also pretty clear in 10k that they need to raise.

They can sell at any price above 1.10. Any number above would be profit if they want to go invest elsewhere.

I am not arguing that GBSN is a good investment. I am saying it can be made profitable.

So the facts changed. Now you have shares that need to be sold at 1.10. That is the new price the stock will trade around until those shares are absorbed but still a better situation than free fall pricing of shares like last year.

One more thing:

There are few important factors per recent filings to keep an eye on:
1) earnings - see how much cash the company has and what the cash burn is. That will tell you when they need to raise money.
2) the holders of the warrants have committed to the company that they won't sell until $3 or $4 and Sep/Oct time frame depending on the circumstance. This is an important factor. The company is not going to do another raise until those investors are paid - this creates a price target for this stock. Of course when the company has not been able to keep commitments in the past, they have renegotiated with the holders so that is important to keep an eye on. Any changes in commitments.
3) the company has 5 FDA/ 6 CE approved assays and one about to to get approval from FDA and another about to be submitted to the FDA - that is no small accomplishment. There could be other companies wanting to get into molecular diagnostics wanting this.
4) at this time the company has 2 million shares in float and have about $1.5 million that they are able to sell shares and add to the float. So far they have shown good responsibility to manage and not just blindly dilute.

These are the only facts right now. The last two years these facts did not exist.

There are two concepts that have worked with this stock -
1) sell and hold
2) Buy when no more shares left to go into float and sell when you make 100% profit

-----
Most importantly this company is very transparent with its timely filings. Follow them. Do research and make decisions just like you will do anything else.

Don't gamble.

First time I invested I lost money. But then I caught on. Since then I have made money twice on this stock.

Does it matter if it is a traders stock? At the end profit is what matters. Greed and fear are the two reactions that make up for he market

From 2016 revenue press release:

We expect to recognize revenue growth from six commercially-available assays beginning in the second half of 2017. We remain focused on cost management efforts which we expect will result in lower cash burn and improved gross and operating margins.”

Earnings are due by the 15th. So should get some news.

Yes - becomes effective tomorrow

But many have made tons of money here as well. Once you understand their filings.

This submission is a stools panel - a lot more complex than the bordatella test. Expect it to come any time. Their submissions typically take 4-5 months. Last one was odd with 2 months

GBSN could actually sell the company for their 6 assays to some major buyer interested in getting into the molecular diagnostics infectious disease market - $25-30 million is where it could go for including the notes it still owes. So I use that as a rule of thumb when considering what is a good price to buy at. Best works when no financing left or outstanding shares all converted to float.

GBSND is going to $3/$4 before it goes down. These price targets are important to achieve so that the note holders they just negotiated with get paid. Toxic financing is removed except for the $3 million left which is in the control of the company. So right now the only one who can dilute is the management of GBSN.

FDA approvals for 510K take a minimum of 90 days.

Which is now outdated.

Adam Feurestein

Doesn't really matter. SEC has already made their decision. They charged those who were engaged in illegal activities. OncoSec was not one of them. Not trying to defend OncoSec here. I was just surprised of all the companies that were involved heavily, why AF chose the ones that were not charged.

From what I read in the Sec filing there was little mention of ONCS and only related to 2013. Lot of other companies had a greater mention in the filing.

I voted no as well.

Keep in mind that they are likely to increase the authorized shares first before they do a reverse split but that will be not be till this Friday.

If everyone buys then it could squeeze higher. Only 15 million shares left that can be converted. At 0.0014 that is only $20k. I won't be surprised if it doubles or triple from here.

0.0022 is possible; $4.00 only with a reverse split.

The reason he was intrigued by it was because it was covered by PBS. Some company likely Merck will partner with OncoSec

300 million shares traded last two days. On Friday had 1.375 billion shares. Only can go up to 1.5 billion. So by tomorrow will likely not have any more shares to sell. At this price a 2000 to 1 rs will only bring share price up to $1.40.

The eventual data decides which drugs and companies succeed. No company goes into developing drugs thinking how to fool investors. Now there maybe some CeOs that do that. But that could ultimately land them in jail because drug development is playing with lives and malicious intent will ultimately could lead to patient death.

Short investors pray for the drug to fail. Long investors see optimism. Ultimately data decides what prevails. Science can be very good. But ultimate value of a drug comes not from the science but its clinical utility. Science helps drugs get to the clinic where their utility gets tested.

That could cause a short squeeze if only 750k shares.

I am not an investor. I am only trading this stock. When the number of shares reaches 1.5 billion, they will not be able to dump more shares into the market.

At 1.5 billion shares and $0.002/share, MC is $3 million. Could get up to $0.005 to $0.01. At $0.005 and 2000 reverse split, would get to $10/share post split.

510Ks take 3-4 months. Fifth assay so expected around March.

Thanks for your input.

They just sold their main drug to another company for $500 million. $200 mil dividend to be payed out; $150 million debt payment; will be left with $159 million and few drug candidates in early phase trials. I see a squeeze with 31% shorts. Technically the company can also buy shares to get dividend on it. I am thinking if 31% of shares short then company only needs to pay dividend for shares not short. Could increase dividend payment/share.

Dividend announced about 10 days ago.

It is 31% sold short. Current SP is only 2X dividend. Could a short squeeze happen? Or would shorts get a due bill?

What do you think of the dividend in $MACK?

http://fortune.com/2016/12/08/rocky-mobile-gaming/

From what i can tell by playing this game is that:
1. At least 24,000 others are playing it. That is likely the minimum.
2. Rocky is addictive - kind of like Battle of the clans.
3. A little difficult. One has to put some money to speed it up otherwise it is not as easy to level up.

Really great ideas. You should send a note to their CEO. Their expenses are low and basically their money is more going into interest payments. They need more liquid cash. Maybe Rocky helps them get that.

Yes - it looked good though I am not a player. It looks it could be a big hit if they get big advertising campaign

The Rocky game is finally out. Looks good!

Inergetics wasn't sold. It was the subsidiary that was sold.